| ObjectiveTo research the combination effect of trastuzumab and oxaliplatin on cell proliferation and viability in HER2-positive gastric cancer and explore the potential possibility and validity of them in clinical application.Methods Through review of literature and western blot,we obtain the HER2-positive gastric cancer cell line NCI-N87 and set three groups(negative control group,trastuzumab group and the combination group).The cell proliferation was determined by clony formation assay and CCK-8 assay.The cell viability was determined bydifferent concentration of trastuzumab and then we combined trastuzumab and oxaliplatin to see whether the effectiveness was better.Further,we established the NCG mouse model for HER2-positive gastric cancer cells and investigated tumorigenicity in vivo through monitoring tumor growth.Data was recorded as mean ± standard deviation,and statistically analyzed with Graphpad Prism 5.0.P < 0.05 was used to indicate a statistically significant difference.ResultsTheclony formation assay showed the clonies number of the combination group was significantly lower than number of trastuzumab group(P<0.01).The cell proliferation assay showed thatthe proliferation rate of the combination groupwas significantly lower than trastuzumab group(P<0.05).The cell viability was gradually decreased with the concentration increasing of trastuzumab,and the cell viability of the combination group wassignificantly lower than trastuzumab group(P<0.05).In mouse model,tumorigenicity in vivo was significantly suppressed in the combination group thantrastuzumab group(P<0.01).ConclusionThe combination of trastuzumab and oxaliplatin could significantly inhibit the cell proliferation and viability of NCI-N87 cells in vitro.Besides,the combination of them could also suppress tumorigenicity in vivo.Our results suggest that combining trastuzumab and oxaliplatinhave practical applications in chemotherapy of gastric cancer. |
PDF Full Text Request